Recombinant human thrombomodulin (rhTM) has anti-inflammatory and anticoagulation activities [2], and it has been suggested as an adjunct therapy for patients with sepsis, particularly those with sepsis-induced coagulopathy [3]. This evidence concerns the gene THBD and Sepsis.